Latest news from Rapha Capital Management & our portfolio companies
FIZE Medical Ltd.
Rapha Capital Management Leads Series A Financing for FIZE Medical Ltd
FIZE’s Novel Device Conquers the Last Frontier in Patient Monitoring
May 4, 2020
ControlRad, Inc.
ControlRad Adds Five People to Leadership Team
December 17, 2019
NexImmune Inc.
NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
- ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant
- IND clearance validates Company’s Artificial Immune Modulation (AIM) nanoparticle technology platform
- Subsequent IND submission to evaluate NEXI-002 in relapsed / refractory Multiple Myeloma patients expected before end of 2019
October 30, 2019
ControlRad, Inc.
ControlRad Announces First Clinical Use of ControlRad Trace Radiation Reduction Technology
Niagara Falls Memorial Medical Center First to Integrate Newly Cleared ControlRad Trace into Fluoroscopically Guided Procedures, Improving Radiation Safety for Patients and Staff
September 23, 2019
Asclepix Therapeutics, Inc.
AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference
To Provide Update on AXT107 Duration of Efficacy Maintained for Over Thirteen Months to Date in Animal Models
AXT107 Inhibits VEGF and Activates Tie2 with Potential Once Yearly Dosing
July 16, 2019
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
Investigational trial results support potential that haploidentical stem cell transplant may be a treatment option for a broader pediatric patient population
July 8, 2019
Marker Therapeutics, Inc.
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
Data selected for oral presentation during a plenary session at AACR’s Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy Conference
Company to host investor event and webcast on Monday, July 22
June 20, 2019